FGL vs PE 22-28
A side-by-side research comparison of FGL and PE 22-28 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FGL | PE 22-28 |
|---|---|---|
| Full name | FGL (NCAM-Derived Peptide) | PE 22-28 (Spadin-Derived TREK-1 Peptide) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research peptide (preclinical) |
| Mechanism | Mimics NCAM FG loop interacting with FGFR1 to promote LTP, neurite outgrowth, neuronal survival, and presynaptic function enhancement. | Selectively blocks the TREK-1 background potassium channel. TREK-1 inhibition enhances serotonergic signaling and rapidly increases synaptogenesis and neurogenesis, producing antidepressant-like effects faster than SSRIs in animal models. |
| Molecular weight | ~1,800 Da | ~ (7-residue peptide) |
| Half-life | 4-8 hours | Short (peptide; improved vs spadin) |
| Bioavailability | Moderate (SubQ, partial BBB crossing) | Intranasal or injection (research) |
| Typical dose | 1-5 mg/kg (research) | Not established for humans |
| Frequency | Daily or every other day | Research only |
| Route | Subcutaneous | Intranasal or injection (research) |
FGL reported benefits
- Synaptic plasticity
- LTP facilitation
- Memory improvement
- Neurotrophic effects
- FGFR activation
PE 22-28 reported benefits
- Rapid antidepressant effects (preclinical)
- Promotes neurogenesis and synaptogenesis
- TREK-1 channel blockade
- Neuroplasticity research interest
Related comparisons
Research and educational reference only. Not medical advice.